Skip to main content
Contact Us
Subscribe
E-Edition
50°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pfizer Inc.
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
March 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
March 16, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
March 10, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
February 28, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 27, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
February 22, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
February 21, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
February 16, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
February 16, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
February 10, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 09, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
January 31, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
January 17, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
January 06, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 03, 2023
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
December 29, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
December 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
December 21, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of January 31 Conference Call with Analysts
December 20, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Presents Updated Favorable Elranatamab Data from Pivotal Phase 2 MagnetisMM-3 Trial
December 10, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Declares First-Quarter 2023 Dividend
December 09, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years
December 08, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
U.S. FDA Accepts for Priority Review the Biologics License Application for Pfizer’s Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV Disease in Older Adults
December 07, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
December 06, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
December 01, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 28, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 11, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
November 04, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
BNTX
PFE
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple Myeloma
November 03, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
PFIZER REPORTS STRONG THIRD-QUARTER 2022 RESULTS AND RAISES 2022 OUTLOOK
November 01, 2022
From
Pfizer Inc.
Via
Business Wire
Tickers
PFE
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.